MedPath

Investigation of the treat-and-extend protocol with Aflibercept in combination with retinal photocoagulation in patients with diabetic macula edema(extension study)

Not Applicable
Conditions
Diabetic macular edema
Registration Number
JPRN-jRCTs031180356
Lead Sponsor
Murata Toshinori
Brief Summary

This study suggested that Treat and Extend therapy with aflibercept combined with retinal photocoagulation is a rational strategy for diabetic macular edema treatments.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
15
Inclusion Criteria

1.Patients with type 1 or type 2 diabetes mellitus 20 years of age or older
2.Patients with fovea involving diabetic macular edema (judged with central subfield thickness on OCT)
3.Patients with reduced visual acuity associated with diabetic macular edema
4.Patients whose best corrected visual acuity is more than 20/320 (24 letters) by the ETDRS visual acuity test.
5.Patients with a central retinal thickness (CRT) of 300 um or more on the OCT retinal map (measured in mm) as an objective finding
6.Patients who are willing and able to visit the study site, as scheduled, and undergo scheduled examinations in this study
7.Patients who can provide written voluntary consent to participate in this study after receiving adequate explanation

Exclusion Criteria

The condition of the fellow eye is worse than that of the study eye.
A history of vitreous surgery, including encircling buckling
Any retinal photocoagulation treatment within 90 days
Topical corticosteroid treatment within 120 days
Treatment with injection of any anti VEGF agent into the study eye within 90 days
Highly active, proliferative diabetic retinopathy in the study eye
A history of uveitis
Aphakic eyes
A history of any intraocular surgery in the study eye within the previous 90 days
It is considered difficult to improve visual acuity due to morphological changes
Glaucoma with poor IOP control, a history of glaucoma filtering surgery, or scheduled filtering surgery in the study eye
IOP of the study eye: more than 25 mmHg
Myopia of -8D or greater
Study eye is the last eye
Optic media in which it is difficult to obtain fundus photographs or OCT images
Severe systemic infections at baseline
Systemic anticoagulation therapy within 180
Poorly controlled diabetes mellitus
Poorly controlled hypertension
A history of cerebrovascular accident and/or myocardial infarction within 180 days
Patients on dialysis and patients with renal failure requiring dialysis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Central retinal thickness (CRT) measured on optical coherence tomography (OCT) and visual acuity.
Secondary Outcome Measures
NameTimeMethod
umber of intravitreal injections of aflibercept and safety.
© Copyright 2025. All Rights Reserved by MedPath